Ad
ABBV - AbbVie Stock Trading
About | AbbVie Inc. (NYSE:ABBV)
None
Quote | AbbVie Inc. (NYSE:ABBV)
| Last: | $144.15 |
|---|---|
| Change Percent: | 0.0% |
| Open: | $143.41 |
| Close: | $144.15 |
| High: | $145.49 |
| Low: | $143.27 |
| Volume: | 4,845,299 |
| Last Trade Date Time: | 12/04/2023 03:00:00 am |
News | AbbVie Inc. (NYSE:ABBV)
-
2023-12-04 16:18:03 ET More on ImmunoGen AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time Immunogen's AbbVie Deal: Key Insights For Investors And Traders AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology Biotechs post record gai...
-
2023-12-03 17:00:00 ET Summary AbbVie has agreed to acquire ImmunoGen for $10 billion, nearly double its previous trading price. The acquisition provides AbbVie with a commercial-stage company and a flagship drug that generated $105 million in sales in Q3. Let's look at this m...
Message Board Posts | AbbVie Inc. (NYSE:ABBV)
| Subject | By | Source | When |
|---|---|---|---|
| whytestocks: $ABBV News Article - AbbVie Stock Plunged: Should You Buy the Dip? | whytestocks | investorshangout | 05/01/2023 7:35:47 PM |
| $ABBV reports 1Q23 resultsraises non-GAAP EPS guidance: | DewDiligence | investorshub | 04/27/2023 12:00:28 PM |
| $ABBVFDA expands Qulipta label_to prevention of chronic migraine: | DewDiligence | investorshub | 04/18/2023 6:23:32 PM |
| Skyrizi phase-3 in UC hits all endpoints: | DewDiligence | investorshub | 03/23/2023 2:02:00 PM |
| $ABBV advances Rinvoq to phase-3 in lupus: | DewDiligence | investorshub | 03/23/2023 2:00:38 PM |
News, Short Squeeze, Breakout and More Instantly...
Ad
- ABBV - ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note | Benzinga
AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $10 billion. The deal, which is expected to close in mid-2024, repre...
-
2023-12-02 10:00:00 ET Over long periods, dividend stocks tend to outperform their non-dividend-paying counterparts. There are likely several reasons for this, one of which is that sustaining a dividend program requires a solid underlying business. So corporations that are able to consisten...
-
2023-11-30 19:19:34 ET The big asset buy in the healthcare industry provided a healthy pop to the two companies involved on Thursday. The stock price of the buyer, sector mainstay AbbVie (NYSE: ABBV) , enjoyed a nearly 3% lift after the news was announced, contrasting quite favorabl...